Disease
5 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 17, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcomes have not yet been assessed or reported.
AUG 13, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
This is a Phase 2 trial registration with no results reported; it describes a planned study of experimental agents in advanced NSCLC with surrogate endpoints (objective response by RECIST), requiring completion and results publication before evidence strength can be assessed.
AUG 13, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
This is a Phase 2 trial registration with no posted results; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
AUG 12, 2026 · PHASE 1/2 TRIAL
ClinicalTrials.gov
This is a first-in-human Phase 1/2 trial registration with no results reported; the study is actively recruiting and designed to establish safety, tolerability, and preliminary efficacy of a novel dual EGFR/HER2 inhibitor in advanced NSCLC.
AUG 11, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a clinical trial registry record describing a planned or ongoing Phase 3 study with no results posted; efficacy and safety data are not yet available in this source.